Pipeline

Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety and efficacy compared to ADCs developed using first-generation technology. Our lead asset, XMT-1536, is a first-in-class Dolaflexin ADC in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. Our next clinical stage ADC, XMT-1592, is expected to enter the clinic in the first half of 2020.

ADC ProgramTargetIndicationPlatformDiscoveryPreclinicalP1P1P2/Pivotal Study
Clinical
XMT-1536
NaPi2b
Ovarian Cancer NSCLC Adenocarcinoma Dolaflexin
Preclinical
XMT-1592
NaPi2b
NSCLC Adenocarcinoma Ovarian Cancer Dolasynthen
Discovery
To Be Named
B7-H4
Multiple Solid Tumors Dolaflexin or Dolasynthen
To Be Named
Multiple
Multiple Solid Tumors Immunosynthen
To Be Named
Multiple
Undisclosed Dolasynthen
To Be Named
Multiple
Undisclosed Dolaflexin
Platform Collaborations
Multiple
Multiple
Undisclosed Dolaflexin
ASN004
5T4
Undisclosed Dolaflexin
DrugIndicationStage
Clinical
XMT-1536
NaPi2b
Ovarian Cancer NSCLC Adenocarcinoma DolaflexinPreclinical
Preclinical
XMT-1592
NaPi2b
NSCLC Adenocarcinoma Ovarian Cancer DolasynthenDiscovery
Discovery
To Be Named
B7-H4
Multiple Solid Tumors Dolaflexin or DolasynthenDiscovery
To Be Named
Multiple
Multiple Solid Tumors ImmunosynthenDiscovery
To Be Named
Multiple
Undisclosed Dolasynthen
To Be Named
Multiple
Undisclosed Dolaflexin
Platform Collaborations
Multiple
Multiple
Undisclosed DolaflexinDiscovery
ASN004
5T4
Undisclosed DolaflexinDiscovery
ADC Program Target Indication Platform Phase
XMT-1536 NaPi2b* Ovarian Cancer NSCLC Adenocarcinoma Dolaflexin P1 Proof of Concept
XMT-1592 NaPi2b* NSCLC Adenocarcinoma Ovarian Cancer Dolasynthen Preclinical
To Be Named B7-H4 Multiple Solid Tumors Dolaflexin or Dolasynthen Preclinical
To Be Named Multiple Multiple Solid Tumors Immunosynthen Discovery
To Be Named Multiple Undisclosed Dolasynthen Discovery
To Be Named Multiple Undisclosed Dolaflexin Discovery
Multiple
EMD Logo
Multiple Undisclosed Dolaflexin Preclinical
ASN004
Asana Logo
5T4 Undisclosed Dolaflexin Preclinical
*NaPi2b is broadly expressed in ovarian cancer and NSCLC adenocarcinoma, as well as other malignant tumor types. NaPi2b is a member of the SLC34 family of sodium-dependent phosphate transporters and plays an important role in maintaining phosphate homeostasis.